We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Swiss biopharmaceuticals company Biopartners has received authorization to market its recombinant growth hormone Valtropin in the European Union (EU), the company said May 4.